Indicator type;Execution Sectors;Total
Units carrying out R&D in Biotechnology;Total;1,636
Units carrying out R&D in Biotechnology;Companies;113
Units carrying out R&D in Biotechnology;Public Administration;68
Units carrying out R&D in Biotechnology;Higher Education;1,444
Units carrying out R&D in Biotechnology;NPPI;11
% Units by type of biotechnology used: Genetic Code;Total;37.2
% Units by type of biotechnology used: Genetic Code;Companies;87.6
% Units by type of biotechnology used: Genetic Code;Public Administration;94.1
% Units by type of biotechnology used: Genetic Code;Higher Education;30.7
% Units by type of biotechnology used: Genetic Code;NPPI;27.3
% Units by type of biotechnology used: Functional Units;Total;43.5
% Units by type of biotechnology used: Functional Units;Companies;86.7
% Units by type of biotechnology used: Functional Units;Public Administration;95.6
% Units by type of biotechnology used: Functional Units;Higher Education;37.6
% Units by type of biotechnology used: Functional Units;NPPI;54.5
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;27.6
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Companies;72.6
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Public Administration;80.9
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;Higher Education;21.3
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering;NPPI;63.6
% Units by type of biotechnology used: Bioprocesses;Total;53.6
% Units by type of biotechnology used: Bioprocesses;Companies;65.5
% Units by type of biotechnology used: Bioprocesses;Public Administration;91.2
% Units by type of biotechnology used: Bioprocesses;Higher Education;50.9
% Units by type of biotechnology used: Bioprocesses;NPPI;54.5
% Units by type of biotechnology used: Subcellular Organisms;Total;13.9
% Units by type of biotechnology used: Subcellular Organisms;Companies;55.8
% Units by type of biotechnology used: Subcellular Organisms;Public Administration;64.7
% Units by type of biotechnology used: Subcellular Organisms;Higher Education;8.1
% Units by type of biotechnology used: Subcellular Organisms;NPPI;36.4
% Units by type of biotechnology used: Bioinformatics;Total;28.7
% Units by type of biotechnology used: Bioinformatics;Companies;71.7
% Units by type of biotechnology used: Bioinformatics;Public Administration;83.8
% Units by type of biotechnology used: Bioinformatics;Higher Education;22.6
% Units by type of biotechnology used: Bioinformatics;NPPI;36.4
% Units by type of biotechnology used: Nanobiotechnology;Total;15.5
% Units by type of biotechnology used: Nanobiotechnology;Companies;53.1
% Units by type of biotechnology used: Nanobiotechnology;Public Administration;73.5
% Units by type of biotechnology used: Nanobiotechnology;Higher Education;9.8
% Units by type of biotechnology used: Nanobiotechnology;NPPI;18.2
% Units by type of biotechnology used: Other;Total;15.7
% Units by type of biotechnology used: Other;Companies;7.1
% Units by type of biotechnology used: Other;Public Administration;7.3
% Units by type of biotechnology used: Other;Higher Education;16.9
% Units by type of biotechnology used: Other;NPPI;9.1
Units in which biotechnology activities are: Main and/or exclusive;Total;676
Units in which biotechnology activities are: Main and/or exclusive;Companies;35
Units in which biotechnology activities are: Main and/or exclusive;Public Administration;5
Units in which biotechnology activities are: Main and/or exclusive;Higher Education;629
Units in which biotechnology activities are: Main and/or exclusive;NPPI;7
Units in which biotechnology activities are: A secondary business line;Total;347
Units in which biotechnology activities are: A secondary business line;Companies;36
Units in which biotechnology activities are: A secondary business line;Public Administration;47
Units in which biotechnology activities are: A secondary business line;Higher Education;262
Units in which biotechnology activities are: A secondary business line;NPPI;2
Units in which biotechnology activities are: A necessary tool for production;Total;613
Units in which biotechnology activities are: A necessary tool for production;Companies;42
Units in which biotechnology activities are: A necessary tool for production;Public Administration;16
Units in which biotechnology activities are: A necessary tool for production;Higher Education;553
Units in which biotechnology activities are: A necessary tool for production;NPPI;2
% Units by final application areas of biotechnology use: Human Health;Total;48.7
% Units by final application areas of biotechnology use: Human Health;Companies;76.1
% Units by final application areas of biotechnology use: Human Health;Public Administration;92.7
% Units by final application areas of biotechnology use: Human Health;Higher Education;44.3
% Units by final application areas of biotechnology use: Human Health;NPPI;72.7
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Total;17.8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Companies;18.6
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Public Administration;61.8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;Higher Education;15.8
% Units by final application areas of biotechnology use: Animal Health and Aquaculture;NPPI;9.1
% Units by final application areas of biotechnology use: Food Products;Total;32.4
% Units by final application areas of biotechnology use: Food Products;Companies;26.6
% Units by final application areas of biotechnology use: Food Products;Public Administration;82.3
% Units by final application areas of biotechnology use: Food Products;Higher Education;30.7
% Units by final application areas of biotechnology use: Food Products;NPPI;0.0
% Units by final application areas of biotechnology use: Agriculture and Forestry;Total;26.4
% Units by final application areas of biotechnology use: Agriculture and Forestry;Companies;21.2
% Units by final application areas of biotechnology use: Agriculture and Forestry;Public Administration;67.7
% Units by final application areas of biotechnology use: Agriculture and Forestry;Higher Education;24.9
% Units by final application areas of biotechnology use: Agriculture and Forestry;NPPI;18.2
% Units by final application areas of biotechnology use: Environment;Total;19.8
% Units by final application areas of biotechnology use: Environment;Companies;23.9
% Units by final application areas of biotechnology use: Environment;Public Administration;75.0
% Units by final application areas of biotechnology use: Environment;Higher Education;16.9
% Units by final application areas of biotechnology use: Environment;NPPI;9.1
% Units by final application areas of biotechnology use: Industry;Total;15.2
% Units by final application areas of biotechnology use: Industry;Companies;18.6
% Units by final application areas of biotechnology use: Industry;Public Administration;66.2
% Units by final application areas of biotechnology use: Industry;Higher Education;12.6
% Units by final application areas of biotechnology use: Industry;NPPI;9.1
R&D personnel in Biotechnology (PP);Total;50,084
R&D personnel in Biotechnology (PP);Companies;15,563
R&D personnel in Biotechnology (PP);Public Administration;16,597
R&D personnel in Biotechnology (PP);Higher Education;17,743
R&D personnel in Biotechnology (PP);NPPI;181
R&D personnel in Biotechnology (PP): Research personnel;Total;32,396
R&D personnel in Biotechnology (PP): Research personnel;Companies;9,798
R&D personnel in Biotechnology (PP): Research personnel;Public Administration;13,026
R&D personnel in Biotechnology (PP): Research personnel;Higher Education;9,445
R&D personnel in Biotechnology (PP): Research personnel;NPPI;127
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;17,688
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Companies;5,765
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Public Administration;3,571
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Higher Education;8,298
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;NPPI;54
R&D personnel in Biotechnology (PP). Women;Total;28,401
R&D personnel in Biotechnology (PP). Women;Companies;9,804
R&D personnel in Biotechnology (PP). Women;Public Administration;8,578
R&D personnel in Biotechnology (PP). Women;Higher Education;9,907
R&D personnel in Biotechnology (PP). Women;NPPI;112
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;17,461
R&D personnel in Biotechnology (PP). Women: Research personnel;Companies;5,851
R&D personnel in Biotechnology (PP). Women: Research personnel;Public Administration;6,435
R&D personnel in Biotechnology (PP). Women: Research personnel;Higher Education;5,104
R&D personnel in Biotechnology (PP). Women: Research personnel;NPPI;71
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;10,939
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Companies;3,953
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Public Administration;2,143
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Higher Education;4,802
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;NPPI;41
R&D personnel in Biotechnology (FTE);Total;35,301.2
R&D personnel in Biotechnology (FTE);Companies;11,442.1
R&D personnel in Biotechnology (FTE);Public Administration;10,721.9
R&D personnel in Biotechnology (FTE);Higher Education;12,993.4
R&D personnel in Biotechnology (FTE);NPPI;143.8
R&D personnel in Biotechnology (FTE): Research personnel;Total;22,324.6
R&D personnel in Biotechnology (FTE): Research personnel;Companies;6,766.8
R&D personnel in Biotechnology (FTE): Research personnel;Public Administration;8,386.7
R&D personnel in Biotechnology (FTE): Research personnel;Higher Education;7,069.9
R&D personnel in Biotechnology (FTE): Research personnel;NPPI;101.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;12,976.7
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Companies;4,675.3
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Public Administration;2,335.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Higher Education;5,923.6
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;NPPI;42.6
R&D personnel in Biotechnology (FTE). Women;Total;20,474.8
R&D personnel in Biotechnology (FTE). Women;Companies;7,280.8
R&D personnel in Biotechnology (FTE). Women;Public Administration;5,633.9
R&D personnel in Biotechnology (FTE). Women;Higher Education;7,471.8
R&D personnel in Biotechnology (FTE). Women;NPPI;88.3
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;12,176.5
R&D personnel in Biotechnology (FTE). Women: Research personnel;Companies;4,080.5
R&D personnel in Biotechnology (FTE). Women: Research personnel;Public Administration;4,171.9
R&D personnel in Biotechnology (FTE). Women: Research personnel;Higher Education;3,870.1
R&D personnel in Biotechnology (FTE). Women: Research personnel;NPPI;54.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;8,298.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Companies;3,200.3
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Public Administration;1,462.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Higher Education;3,601.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;NPPI;34.3
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;2,565,367
Expenditure on internal R&D in Biotechnology (thousands of euros);Companies;775,164
Expenditure on internal R&D in Biotechnology (thousands of euros);Public Administration;554,906
Expenditure on internal R&D in Biotechnology (thousands of euros);Higher Education;1,223,801
Expenditure on internal R&D in Biotechnology (thousands of euros);NPPI;11,496
1) By type of expenditure: Current expenditure;Total;2,359,528
1) By type of expenditure: Current expenditure;Companies;727,099
1) By type of expenditure: Current expenditure;Public Administration;513,043
1) By type of expenditure: Current expenditure;Higher Education;1,108,189
1) By type of expenditure: Current expenditure;NPPI;11,197
1.1) Labour expenditure of research personnel;Total;950,162
1.1) Labour expenditure of research personnel;Companies;267,235
1.1) Labour expenditure of research personnel;Public Administration;318,977
1.1) Labour expenditure of research personnel;Higher Education;360,922
1.1) Labour expenditure of research personnel;NPPI;3,027
1.2) Labour expenditure of technical and auxiliary personnel;Total;421,784
1.2) Labour expenditure of technical and auxiliary personnel;Companies;128,800
1.2) Labour expenditure of technical and auxiliary personnel;Public Administration;71,268
1.2) Labour expenditure of technical and auxiliary personnel;Higher Education;220,540
1.2) Labour expenditure of technical and auxiliary personnel;NPPI;1,176
1.3) Other current expenditure;Total;987,583
1.3) Other current expenditure;Companies;331,063
1.3) Other current expenditure;Public Administration;122,798
1.3) Other current expenditure;Higher Education;526,727
1.3) Other current expenditure;NPPI;6,994
2) By type of expenditure: Capital expenditure;Total;205,839
2) By type of expenditure: Capital expenditure;Companies;48,066
2) By type of expenditure: Capital expenditure;Public Administration;41,862
2) By type of expenditure: Capital expenditure;Higher Education;115,612
2) By type of expenditure: Capital expenditure;NPPI;299
2.1) Land and buildings;Total;30,577
2.1) Land and buildings;Companies;6,521
2.1) Land and buildings;Public Administration;7,162
2.1) Land and buildings;Higher Education;16,843
2.1) Land and buildings;NPPI;52
2.2) Equipment and tools;Total;136,544
2.2) Equipment and tools;Companies;39,416
2.2) Equipment and tools;Public Administration;33,362
2.2) Equipment and tools;Higher Education;63,527
2.2) Equipment and tools;NPPI;239
2.3) Acquisition of specific R&D software;Total;7,117
2.3) Acquisition of specific R&D software;Companies;1,945
2.3) Acquisition of specific R&D software;Public Administration;1,211
2.3) Acquisition of specific R&D software;Higher Education;3,959
2.3) Acquisition of specific R&D software;NPPI;3
2.4) Other R&D-specific IP products;Total;31,601
2.4) Other R&D-specific IP products;Companies;184
2.4) Other R&D-specific IP products;Public Administration;128
2.4) Other R&D-specific IP products;Higher Education;31,284
2.4) Other R&D-specific IP products;NPPI;5
1.1) By origin of funds: Own funds;Total;1,030,214
1.1) By origin of funds: Own funds;Companies;78,546
1.1) By origin of funds: Own funds;Public Administration;90,048
1.1) By origin of funds: Own funds;Higher Education;860,603
1.1) By origin of funds: Own funds;NPPI;1,016
1.2) By origin of funds: Funds from the Business sector;Total;277,770
1.2) By origin of funds: Funds from the Business sector;Companies;115,144
1.2) By origin of funds: Funds from the Business sector;Public Administration;27,808
1.2) By origin of funds: Funds from the Business sector;Higher Education;128,002
1.2) By origin of funds: Funds from the Business sector;NPPI;6,816
1.3) By origin of funds: Funds from the Public Administration sector;Total;951,439
1.3) By origin of funds: Funds from the Public Administration sector;Companies;458,700
1.3) By origin of funds: Funds from the Public Administration sector;Public Administration;372,119
1.3) By origin of funds: Funds from the Public Administration sector;Higher Education;119,498
1.3) By origin of funds: Funds from the Public Administration sector;NPPI;1,122
1.4) By origin of funds: Funds from the Higher Education sector;Total;4,307
1.4) By origin of funds: Funds from the Higher Education sector;Companies;1,537
1.4) By origin of funds: Funds from the Higher Education sector;Public Administration;2,122
1.4) By origin of funds: Funds from the Higher Education sector;Higher Education;647
1.4) By origin of funds: Funds from the Higher Education sector;NPPI;0
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;52,107
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Companies;28,686
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Public Administration;9,445
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Higher Education;12,986
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;NPPI;990
1.6) By origin of funds: Funds from the rest of the world;Total;249,530
1.6) By origin of funds: Funds from the rest of the world;Companies;92,551
1.6) By origin of funds: Funds from the rest of the world;Public Administration;53,363
1.6) By origin of funds: Funds from the rest of the world;Higher Education;102,065
1.6) By origin of funds: Funds from the rest of the world;NPPI;1,551
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;171,660
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Companies;35,006
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Public Administration;13,038
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Higher Education;123,396
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);NPPI;220
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;131,863
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Companies;30,282
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Public Administration;12,385
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Higher Education;88,985
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;NPPI;212
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;39,797
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Companies;4,725
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Public Administration;653
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Higher Education;34,412
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;NPPI;8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;41.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Companies;57.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Public Administration;52.9
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Higher Education;39.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital;NPPI;72.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;14.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Companies;8.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Public Administration;14.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Higher Education;15.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;NPPI;9.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;24.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Companies;46.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Public Administration;36.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Higher Education;22.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;NPPI;18.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;13.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Companies;23.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Public Administration;35.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Higher Education;12.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;NPPI;9.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;19.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Companies;28.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Public Administration;44.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Higher Education;17.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;NPPI;27.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Companies;28.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Public Administration;38.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Higher Education;17.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;NPPI;18.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;15.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Companies;10.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Public Administration;10.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Higher Education;16.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;NPPI;9.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;41.3
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Companies;40.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Public Administration;39.7
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Higher Education;41.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;NPPI;36.4
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;51.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Companies;62.8
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Public Administration;51.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Higher Education;50.2
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost;NPPI;63.6
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;20.0
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Companies;19.5
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Public Administration;19.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Higher Education;20.1
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;NPPI;18.2